Faes Farma SA (FAE)
Madrid Stock Exchange · Spain · prices in EUR · close of 27 Oct 2026
Key indicators
| Last close | EUR 4.740 |
|---|---|
| 52-week range | 4.315 – 5.440 |
| Return, 1 month / 3 months | +1.1% / +2.9% |
| Return, 1 year / 3 years | +7.4% / +80.6% |
| Trend | Uptrend |
| RSI (14) | 52 |
| Volatility (1 year) | 21.7% |
| Worst drawdown (1 year) | -17.5% |
| Average daily value traded | 0.73M EUR |
| Dividend yield | 2.2% |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Faes Farma is a Spanish pharmaceutical company based in the Basque Country. It researches, develops, manufactures and markets prescription medicines and over-the-counter products, with a focus on allergies, bone health and digestive care, and it also supplies active pharmaceutical ingredients to other drugmakers. Its products reach pharmacies, hospitals and healthcare professionals in Spain and through its international operations, and the company has a long history in the pharmaceutical sector.
Faes Farma SA trades under the code FAE on the Madrid Stock Exchange in Spain, with its price quoted in euros (EUR). Our dividend records, which start in 2019, show payments in 8 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Faes Farma SA (FAE) trades on the Madrid Stock Exchange in Spain. It last closed at EUR 4.740 on 27 October 2026.
Its price-based Market X-Ray is 63 out of 100 (a fair price profile), ranking 62 of 236 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 7.4% and over the last three months it rose 2.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Madrid Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 58 · Fair | Mixed trend against its averages. | |
| Above 200-day average | 1.5% | ||
| From 52-week high | -11.9% | ||
| Momentum | 69 · Fair | Typical recent returns for this exchange. | |
| 3-month return | 2.9% | ||
| 6-month return | 0.6% | ||
| 12-month return, skipping the last month | 6.3% | ||
| Stability (higher is calmer) | 59 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 21.7% | ||
| Worst drawdown, 1 year (smaller is calmer) | -17.5% | ||
| Liquidity | 75 · Strong | Trades actively. | |
| Average daily value traded | 0.73M EUR | ||
| Zero-volume days | 0.0% | ||
| Income | 58 · Fair | Dividend is typical for this exchange. | |
| Dividend yield | 2.2% | ||
| Years with dividends | 6 |
Strengths
- Liquidity: Trades actively.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −2.2% |
|---|---|
| 1 month | +1.1% |
| 3 months | +2.9% |
| 6 months | +0.6% |
| 1 year | +7.4% |
| 3 years | +80.6% |
| 5 years | +65.1% |
Signals
| 50-day / 200-day average | 4.629 / 4.668 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.109 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 2 Jul 2026 | EUR 0.0705 |
| 8 Jan 2026 | EUR 0.0332 |
| 3 Jul 2025 | EUR 0.1118 |
| 9 Jan 2025 | EUR 0.0332 |
| 4 Jul 2024 | EUR 0.0940 |
| 11 Jan 2024 | EUR 0.0316 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Madrid Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.